Status:
TERMINATED
BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r)
Lead Sponsor:
Community Research Initiative of New England
Collaborating Sponsors:
Abbott
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study will look to see if increasing the standard dose of Kaletra is tolerated and if it will lower viral loads to undetectable levels. This study will also look at the pharmacokinetic data (amou...
Detailed Description
There are several reasons for low level viremia in patients on Kaletra (LPV/r), including poor adherence, incomplete absorption, cellular drug pumps or resistance mutations. Increasing exposure to pro...
Eligibility Criteria
Inclusion
- CD4 Count \>50
- Viral load 200-75,000 on two most recent measures
- More than 16 weeks on standard dose Kaletra (LPV/r)
- May be initial PI regimen or prior PI usage
- Up to 50-fold resistance to LPV/r
Exclusion
- Age \< 18 years old
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
End Date :
April 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00414284
Start Date
June 1 2006
End Date
April 1 2007
Last Update
December 8 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Community Research Initiative of New England - Boston
Boston, Massachusetts, United States, 02215